Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EXFORGE vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Exforge is a combination of amlodipine, a dihydropyridine calcium channel blocker, and valsartan, an angiotensin II receptor blocker. Amlodipine inhibits calcium influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation. Valsartan selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation and reduced aldosterone secretion.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Treatment of hypertension,Management of hypertension in patients who are not adequately controlled on monotherapy,Initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
Hypertension
One tablet orally once daily. Initial dose: 5/160 mg or 5/320 mg. Titrate based on blood pressure response. Maximum dose: 10/320 mg once daily.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Amlodipine: terminal elimination half-life is 30-50 hours (mean ~35 h), supporting once-daily dosing. Valsartan: terminal half-life is approximately 6 hours, with the combination product dosed once daily due to amlodipine's long half-life.
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Amlodipine is extensively metabolized in the liver via CYP3A4 to inactive metabolites. Valsartan is primarily eliminated unchanged in feces and urine; only about 20% is metabolized by CYP2C9.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Valsartan is primarily eliminated via biliary excretion (83%) in feces as unchanged drug; renal excretion accounts for 13% (mostly unchanged). Amlodipine is extensively metabolized in the liver, with 60% of metabolites excreted renally and 20-25% in feces as unchanged drug.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Amlodipine: ~93% bound to plasma proteins. Valsartan: 94-97% bound to serum albumin.
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
Amlodipine: Vd is approximately 21 L/kg, indicating extensive extravascular distribution. Valsartan: Vd is about 17 L, not weight-adjusted, indicating distribution mainly in plasma and extracellular fluid.
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Oral bioavailability: Amlodipine 64-90%; Valsartan about 25% (with wide interindividual variability). Food decreases valsartan absorption by about 40-50%, but does not affect amlodipine absorption.
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
For GFR 30-60 m L/min: no adjustment. For GFR <30 m L/min: not recommended due to lack of data. Contraindicated if GFR <30 m L/min due to hydrochlorothiazide component.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: not recommended. Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Safety and efficacy not established in pediatric patients below 18 years.
Not established; avoid use in children.
No dose adjustment required based on age alone. Initiate at lower end of dosing range (5/160 mg) due to potential for increased sensitivity to hypotension. Monitor renal function closely.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
Exforge contains valsartan, which can cause fetal harm when used during pregnancy. If pregnancy is detected, discontinue Exforge as soon as possible.
None
Fetal toxicity,Hypotension in salt- or volume-depleted patients,Impaired renal function,Hyperkalemia,Angioedema,Hepatic impairment,Severe obstructive coronary artery disease
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Pregnancy,Hypersensitivity to amlodipine, valsartan, or any component of the formulation,Concomitant use with aliskiren in patients with diabetes
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Avoid grapefruit juice (increases amlodipine AUC by 56%). High-potassium foods (bananas, oranges, spinach) may increase hyperkalemia risk; no specific restriction but monitor intake if renal impairment.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
Pregnancy Category D. First trimester: Potential fetal toxicity; risk of malformations not significantly increased based on limited data. Second and third trimesters: Oligohydramnios, fetal renal dysfunction, skull ossification defects, hypotension, hyperkalemia, and anuria due to angiotensin II receptor antagonist (valsartan) component. Amlodipine may cause fetal hypoxia due to uterine hypoperfusion.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
No data on Exforge in breast milk. Valsartan is excreted in rat milk; amlodipine is excreted in human milk (M/P ratio unknown). Due to potential adverse effects in nursing infants (hypotension, renal effects), avoid breastfeeding. If used, monitor infant for hypotension and renal function.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
Exforge is contraindicated in pregnancy. No dose adjustment can mitigate fetal risk. Alternative antihypertensive therapy is recommended. If inadvertently used, discontinue immediately and switch to a safe alternative.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
EXFORGE (amlodipine/valsartan) combines a dihydropyridine calcium channel blocker with an angiotensin II receptor blocker. It is contraindicated in pregnancy (fetal nephrotoxicity, oligohydramnios). Monitor serum potassium and renal function, especially in older adults, volume-depleted patients, or those with renal impairment. Avoid use with aliskiren in patients with diabetes or GFR <60 m L/min. Peripheral edema is less than amlodipine alone due to vasodilation balance.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Do not take if pregnant or planning pregnancy; use effective contraception.,Avoid grapefruit juice as it increases amlodipine levels and risk of hypotension.,Take the same time each day; do not skip doses or double up.,May cause dizziness or lightheadedness; avoid driving until you know how it affects you.,Report swelling in hands/feet, irregular heartbeat, or signs of angioedema (swelling of face/lips).
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EXFORGE vs ALDORIL 25, answered by our medical review team.
EXFORGE is a Antihypertensive that works by Exforge is a combination of amlodipine, a dihydropyridine calcium channel blocker, and valsartan, an angiotensin II receptor blocker. Amlodipine inhibits calcium influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation. Valsartan selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation and reduced aldosterone secretion.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EXFORGE and ALDORIL 25 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EXFORGE is: One tablet orally once daily. Initial dose: 5/160 mg or 5/320 mg. Titrate based on blood pressure response. Maximum dose: 10/320 mg once daily.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EXFORGE and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EXFORGE is classified as Category C. Pregnancy Category D. First trimester: Potential fetal toxicity; risk of malformations not significantly increased based on limited data. Second and third trimesters: Oligohydramni. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.